SEC Info - Avant Diagnostics, Inc. - ‘3’ for 6/5/20 re: Theralink Technologies, Inc.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Avant Diagnostics, Inc

(Last)

(First)

(Middle)

15000 W. 6TH AVE., SUITE 400

(Street)

GOLDEN

80401

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
6/5/20

3. Issuer Name and Ticker or Trading Symbol
OncBioMune Pharmaceuticals, Inc [ OBMP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series D-1 Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock, par value $.0001 per share	⁽¹⁾	⁽¹⁾	D

Explanation of Responses:

(1) The Reporting Person owns 1,000 shares of Series D-1 Convertible Preferred Stock which were acquired on June 5, 2020 as consideration for the sale of substantially all of the assets of the Reporting Person to the Issuer (the "Asset Sale"). The shares of Series D-1 Convertible Preferred Stock have no expiration date and shall automatically convert into 54.55% of the Issuer's fully diluted shares of common stock after giving effect to the transactions contemplated by the Asset Sale upon the effectiveness of an amendment to the Issuer's articles of incorporation to increase its authorized shares of common stock, which based on information included in the Issuer's Current Report on Form 8-K filed with the SEC on June 11, 2020, is expected to be approximately 4,441,400,000 shares, or approximately 99% of the Issuer's voting capital stock. The Series D-1 Convertible Preferred Stock votes on an as-converted basis with the Issuer's common stock prior to its conversion.

	/s/ Michael Ruxin M.D., CEO	6/15/20
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Avant Diagnostics, Inc. – ‘3’ for 6/5/20 re: Theralink Technologies, Inc.

On: Monday, 6/15/20, at 5:13pm ET · For: 6/5/20 · Accession #: 1493152-20-11195 · File #: 0-52218

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents

This ‘3’ Document is an XML Data File that may be rendered in various formats:

Avant Diagnostics, Inc. – ‘3’ for 6/5/20 re: Theralink Technologies, Inc.

On: Monday, 6/15/20, at 5:13pm ET · For: 6/5/20 · Accession #: 1493152-20-11195 · File #: 0-52218

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34Filing Table of Contents

This ‘3’ Document is an XML Data File that may be rendered in various formats:

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents